MedPath

ITB-MED LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Phase 1
Active, not recruiting
Conditions
ALS
Interventions
Biological: TCD601
First Posted Date
2024-06-12
Last Posted Date
2024-08-12
Lead Sponsor
ITB-Med LLC
Target Recruit Count
48
Registration Number
NCT06453668
Locations
🇸🇪

Umeå University Hospital, Umeå, Sweden

🇸🇪

Skåne University Hospital Malmö, Malmö, Sweden

🇸🇪

Studieenheten Akademiskt Specialistcentrum, Stockholm, Sweden

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2024-04-15
Last Posted Date
2025-01-29
Lead Sponsor
ITB-Med LLC
Target Recruit Count
33
Registration Number
NCT06365437
Locations
🇸🇪

Skåne University Hospital, Malmö, Sweden

🇸🇪

Sahlgrenska University Hospital, Göteborg, Sweden

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 4 locations

A Study of TCD601 (siplizumab) in New Onset Type 1 Diabetes Patients

Phase 2
Active, not recruiting
Conditions
Diabetes Mellitus, Type 1
Interventions
Other: Placebo
First Posted Date
2023-09-06
Last Posted Date
2025-03-05
Lead Sponsor
ITB-Med LLC
Target Recruit Count
96
Registration Number
NCT06025110
Locations
🇧🇪

UZ Brussel, Brussel, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

🇮🇹

Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy

and more 23 locations

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Phase 2
Active, not recruiting
Conditions
Liver Transplantation
Interventions
First Posted Date
2023-08-31
Last Posted Date
2024-11-27
Lead Sponsor
ITB-Med LLC
Target Recruit Count
12
Registration Number
NCT06019507
Locations
🇸🇪

Karolinska University Hospital, Stockholm, Huddinge, Sweden

A Study of TCD601 in de Novo Renal Transplant Recipients

Phase 2
Active, not recruiting
Conditions
Renal Transplantation
Interventions
First Posted Date
2022-12-30
Last Posted Date
2025-04-17
Lead Sponsor
ITB-Med LLC
Target Recruit Count
90
Registration Number
NCT05669001
Locations
🇺🇸

Scripps Green Hospital, La Jolla, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

University of California Davis Medical Center, Sacramento, California, United States

and more 24 locations

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Phase 2
Active, not recruiting
Conditions
Kidney Transplantation
Interventions
First Posted Date
2021-03-17
Last Posted Date
2025-04-17
Lead Sponsor
ITB-Med LLC
Target Recruit Count
18
Registration Number
NCT04803006
Locations
🇺🇸

UCSF Connie Frank Transplant Center, San Francisco, California, United States

🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Cooperman Barnabas Medical Center, Livingston, New Jersey, United States

and more 2 locations

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Phase 2
Active, not recruiting
Conditions
Kidney Transplantation
Interventions
First Posted Date
2021-03-17
Last Posted Date
2025-04-17
Lead Sponsor
ITB-Med LLC
Target Recruit Count
18
Registration Number
NCT04803058
Locations
🇰🇷

Samsung Medical University, Seoul, Korea, Republic of

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 3 locations

A Dose Escalation Study in de Novo Renal Transplantation

Phase 2
Completed
Conditions
Kidney Transplantation
Interventions
First Posted Date
2020-03-17
Last Posted Date
2025-02-27
Lead Sponsor
ITB-Med LLC
Target Recruit Count
13
Registration Number
NCT04311632
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Kansas University Medical Center, Kansas City, Kansas, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath